Novartis Recalls Dexmethylphenidate HCl Extended-Release Capsules for Dissolution Failure
Novartis Pharmaceuticals Corp. is recalling 10,767 bottles of Dexmethylphenidate HCl Extended-Release capsules because stability testing showed the product failed to meet dissolution specifications.
What this means for you
Cosmetic or documentation issue. No expected health impact, but the manufacturer is correcting the affected products.
Our severity reasoning: The recall is classified as FDA Class III, which by definition is unlikely to cause adverse health consequences. The issue is a documentation/stability specification failure without reported injuries or illnesses.
Plain-English summary
Novartis Pharmaceuticals Corp. is recalling 10,767 bottles of Dexmethylphenidate HCl Extended-Release, Capsules, 10mg, Rx only, 100 Capsules. The product was manufactured by Alkermes Gainesville LLC for Sandoz Inc. The specific lot affected is F0002, with an expiration date of 12/2016.
The recall was initiated because the product failed to meet dissolution specifications. Specifically, an out-of-specification result (above specification) was obtained at the 6-hour dissolution time point during 12-month stability testing. This indicates the medication may not release the active ingredient at the intended rate.
The affected product was distributed to a site in New Jersey. Consumers and healthcare providers should stop using the recalled product and contact their healthcare provider or pharmacist for guidance on obtaining a replacement or alternative treatment.
The recalled product
- Product
- Dexmethylphenidate HCl Extended-Release, Capsules, 10mg, Rx only, 100 Capsules. Manufactured by Alkermes Gainesville LLC Gainesville, GA 30504 for Sandoz Inc. Princeton, NJ 08540
- Manufacturer
- Novartis Pharmaceuticals Corp.
- Category
- Drug — Prescription Medication
- Hazard
- Affected units
- 10,767
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: F0002
- Exp 12/2016
Distribution
Distribution scope not specified by the agency.
Related recalls
Same manufacturer · Novartis Pharmaceuticals Corp.
See all →- SevereNovartis Withdraws SANDIMMUNE Oral Solution Bottles Due to Crystallization
FDA (Drugs) · 2023-09-27
- CriticalNovartis Recalls Promacta Oral Suspension Due to Peanut Cross-Contamination
FDA (Drugs) · 2019-05-29
- LowNovartis Recalls Isopto Carpine Eye Drops for Impurity Failures
FDA (Drugs) · 2017-05-03
- ModerateNovartis Recalls Pilocarpine Hydrochloride Ophthalmic Solution for Impurity Failures
FDA (Drugs) · 2017-05-03
- LowNovartis Recalls Foradil Aerolizer Inhalation Powder Due to Stability Failure
FDA (Drugs) · 2015-06-24
Same hazard · dissolution failure
See all →- ModerateApotex Recalls Paxil Tablets for Failed Dissolution and Stability Testing
FDA (Drugs) · 2026-09-02
- ModerateMylan Recalls Acamprosate Calcium Tablets Due to Dissolution Failure
FDA (Drugs) · 2026-08-26
- ModerateChlorthalidone 25mg tablets failed dissolution specifications in two batches
FDA (Drugs) · 2026-06-24
- ModerateNiacin extended-release tablets failed dissolution testing at 24 hours
FDA (Drugs) · 2026-06-17
- ModerateMinocycline extended-release tablets failed dissolution testing during stability analysis
FDA (Drugs) · 2026-06-17